All AbMole products are for research use only, cannot be used for human consumption.
Nimotuzumab (Nimotuzumab) is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). Nimotuzumab has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). EGFR is overexpressed in a variety of solid tumors, such as head and neck cancer, lung cancer and colorectal cancer. EGFR overexpression is highly associated with high aggressiveness, high metastasis, and poor prognosis. Nimotuzumab can competitively bind EGFR and block downstream signal transduction pathway mediated by EGFR, thereby inhibiting tumor cell proliferation, inducing differentiation, promoting apoptosis and inhibiting tumor angiogenesis. Nimotuzumab failed to recognize mouse EGFR.
Another CAS# 780758-10-3
| Molecular Weight | 147656.97 |
| Formula | C6566H10082N1746O2056S40 |
| CAS Number | 828933-51-3 |
| Storage | -80°C for long term |
| Related EGFR/HER2 Products |
|---|
| Sevabertinib
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity. |
| BPIQ-I
BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor.. |
| HKI-357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. |
| SJF-1528
SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells. |
| CH7233163
CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
